There are 108 resources available
Q&A and live discussion
Presenter: Javier Cortés
Session: Proffered Paper - Breast cancer, early stage
Resources:
Webcast
Invited Discussant LBA12 and 161O
Presenter: Serena Di Cosimo
Session: Proffered Paper - Breast cancer, early stage
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Javier Cortés
Session: Proffered Paper - Breast cancer, early stage
Resources:
Webcast
LBA65 - The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
Presenter: Daniel Renouf
Session: Proffered Paper - GI, non colorectal
Resources:
Abstract
Slides
Webcast
1525O - The QOLIXANE trial - Real life QoL and efficacy data in 1st line pancreatic cancer from the prospective platform for outcome, quality of life, and translational research on pancreatic cancer (PARAGON) registry
Presenter: Thorsten Götze
Session: Proffered Paper - GI, non colorectal
Resources:
Abstract
Slides
Webcast
360O - Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link?
Presenter: Michael Weller
Session: Proffered Paper - CNS tumours
Resources:
Abstract
Slides
Webcast
361O - Defining the prognostic role of MGMT methylation value by pyrosequencing assay in glioblastoma patients: A large Italian multicenter study
Presenter: Mario Caccese
Session: Proffered Paper - CNS tumours
Resources:
Abstract
Slides
Webcast
159O - Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group
Presenter: Vincent De Jong
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Webcast
160O - Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)
Presenter: Andreas Schneeweiss
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA12 - PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer
Presenter: Erica Mayer
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast